- Home
- REBN vs GNPX Comparison
REBN vs GNPX Comparison
Compare REBN & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- GNPX
- Stock Information
- Founded
- REBN 2015
- GNPX 2009
- Country
- REBN United States
- GNPX United States
- Employees
- REBN N/A
- GNPX N/A
- Industry
- REBN Restaurants
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- GNPX Health Care
- Exchange
- REBN Nasdaq
- GNPX Nasdaq
- Market Cap
- REBN 13.3M
- GNPX 10.8M
- IPO Year
- REBN 2022
- GNPX 2018
- Fundamental
- Price
- REBN $2.11
- GNPX $7.12
- Analyst Decision
- REBN
- GNPX
- Analyst Count
- REBN 0
- GNPX 0
- Target Price
- REBN N/A
- GNPX N/A
- AVG Volume (30 Days)
- REBN 57.7K
- GNPX 1.7M
- Earning Date
- REBN 11-18-2025
- GNPX 11-12-2025
- Dividend Yield
- REBN N/A
- GNPX N/A
- EPS Growth
- REBN N/A
- GNPX N/A
- EPS
- REBN N/A
- GNPX N/A
- Revenue
- REBN $6,565,623.00
- GNPX N/A
- Revenue This Year
- REBN $335.98
- GNPX N/A
- Revenue Next Year
- REBN N/A
- GNPX N/A
- P/E Ratio
- REBN N/A
- GNPX N/A
- Revenue Growth
- REBN 14.03
- GNPX N/A
- 52 Week Low
- REBN $1.03
- GNPX $6.62
- 52 Week High
- REBN $8.30
- GNPX $149.50
- Technical
- Relative Strength Index (RSI)
- REBN 36.65
- GNPX 65.32
- Support Level
- REBN $2.14
- GNPX $6.62
- Resistance Level
- REBN $2.37
- GNPX $9.89
- Average True Range (ATR)
- REBN 0.14
- GNPX 1.11
- MACD
- REBN 0.00
- GNPX 0.56
- Stochastic Oscillator
- REBN 15.31
- GNPX 54.29
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.